Clinical Trial Update: Safety and Efficacy of YB-1113 in Treatment of POI [Phase 1]

View source ↗

Summary

This is a Phase 1 trial evaluating the safety and initial efficacy of YB-1113 for premature ovarian insufficiency. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ovarian Insufficiency

Drugs mentioned

• YB-1113

Snippet

Sponsor: Bright Cell, Inc. | Conditions: POI | Phase 1 | Status: NOT_YET_RECRUITING